A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors.

Study start date: July 1, 1997

DISEASE CHARACTERISTICS: Histologically proven recurrent or refractory pediatric solid tumor Bone marrow metastases allowed PATIENT CHARACTERISTICS: Age: 1 to 30 Performance status: 0-2 Life expectancy: At least 2 months Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 (transfusion independent) Hemoglobin at least 10 g/dL (RBC transfusion allowed) Hepatic: Bilirubin no greater than 1.5 times normal SGOT no greater than 2.5 times normal Renal: Adequate renal function as defined by one of the following: GFR by creatinine clearance Radioisotope GFR Iothalamate at least 70 mL/min Cardiovascular: Adequate cardiac function as defined by one of the following: Ejection fraction at least 55% by MUGA Fractional shortening at least 28% by echocardiogram Neurologic: Adequate CNS function as defined by: Seizure disorder, if present, controlled by anticonvulsants CNS toxicity no greater than grade 2 Other: No uncontrolled infections Not pregnant or nursing No allergy to platinum compounds No history of allergy to etoposide (unless mobilization phase not required) PRIOR CONCURRENT THERAPY: Biologic therapy: Recovered from prior immunotherapy At least 1 week since prior cytokines At least 3 months since prior bone marrow or peripheral blood stem cell transplantation No concurrent immunomodulator No concurrent cytokines Chemotherapy: At least 3 weeks (6 for nitrosourea) since prior chemotherapy and recovered No prior thiotepa No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: Recovered from prior radiotherapy At least 6 months since prior total body irradiation conditioning No concurrent radiotherapy to greater than 10% of total liver, lung, or bone marrow Surgery: Not specified